Changes

[[American Mistletoe]] ([[Wikipedia:Phoradendron serotinum|Phoradendron serotinum]]) has a history of use in Mexican and South American traditional medicine for the treatment of cancer.<ref>{{cite journal | vauthors=((Alonso-Castro, A. J.)), ((Juárez-Vázquez, M. del C.)), ((Domínguez, F.)), ((González-Sánchez, I.)), ((Estrada-Castillón, E.)), ((López-Toledo, G.)), ((Chávez, M.)), ((Cerbón, M. A.)), ((García-Carranca, A.)) | journal=Journal of Ethnopharmacology | title=The antitumoral effect of the American mistletoe Phoradendron serotinum (Raf.) M.C. Johnst. (Viscaceae) is associated with the release of immunity-related cytokines | volume=142 | issue=3 | pages=857–864 | date=1 August 2012 | url=https://www.sciencedirect.com/science/article/pii/S0378874112004175 | doi=10.1016/j.jep.2012.06.018 | access-date=13 March 2023}}</ref>

[[American Mistletoe]] ([[Wikipedia:Phoradendron serotinum|Phoradendron serotinum]]) has a history of use in Mexican and South American traditional medicine for the treatment of cancer.<ref>{{cite journal | vauthors=((Alonso-Castro, A. J.)), ((Juárez-Vázquez, M. del C.)), ((Domínguez, F.)), ((González-Sánchez, I.)), ((Estrada-Castillón, E.)), ((López-Toledo, G.)), ((Chávez, M.)), ((Cerbón, M. A.)), ((García-Carranca, A.)) | journal=Journal of Ethnopharmacology | title=The antitumoral effect of the American mistletoe Phoradendron serotinum (Raf.) M.C. Johnst. (Viscaceae) is associated with the release of immunity-related cytokines | volume=142 | issue=3 | pages=857–864 | date=1 August 2012 | url=https://www.sciencedirect.com/science/article/pii/S0378874112004175 | doi=10.1016/j.jep.2012.06.018 | access-date=13 March 2023}}</ref>

==History of Clinical Use==

==History of Clinical Use==

==Scientific Evidence==

==Scientific Evidence==

[[File:Pubmed image2.png|alt=|none|thumb|450x450px|Cumulative PubMed articles by year with the terms "Mistletoe" and "Cancer"]]

[[File:Pubmed image2.png|alt=|thumb|450x450px|Cumulative PubMed articles by year with the terms "Mistletoe" and "Cancer"]]

===Safety Trials===

===Safety Trials===

A phase 2, single arm study of osteosarcoma patients with fully resected pulmonary metastases will be conducted at [[:en:MD_Anderson_Cancer_Center|University of Texas MD Anderson Cancer Center]]. Participants will receive Iscador® Pini as a prophylactic immunotherapy.<ref>https://beta.clinicaltrials.gov/study/NCT05726383</ref> This trial replicates in part  the 2007 two armed study of post relapse disease free survival in fully resected osteosarcoma. One arm receiving etoposide had an average survival of 7 months (all had recurrence) and the other receiving Iscador Pini had a median survival of 106 months (5 out of 9 without recurrence).<ref>{{cite journal | vauthors=((Longhi, A.)), ((Cesari, M.)), ((Serra, M.)), ((Mariani, E.)) | journal=Sarcoma | title=Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse | volume=2020 | pages=e8260730 | date=27 April 2020 | url=https://www.hindawi.com/journals/sarcoma/2020/8260730/ | doi=10.1155/2020/8260730 | access-date=15 March 2023}}</ref>

A phase 2, single arm study of osteosarcoma patients with fully resected pulmonary metastases will be conducted at [[:en:MD_Anderson_Cancer_Center|University of Texas MD Anderson Cancer Center]]. Participants will receive Iscador® Pini as a prophylactic immunotherapy.<ref>https://beta.clinicaltrials.gov/study/NCT05726383</ref> This trial replicates in part  the 2007 two armed study of post relapse disease free survival in fully resected osteosarcoma. One arm receiving etoposide had an average survival of 7 months (all had recurrence) and the other receiving Iscador Pini had a median survival of 106 months (5 out of 9 without recurrence).<ref>{{cite journal | vauthors=((Longhi, A.)), ((Cesari, M.)), ((Serra, M.)), ((Mariani, E.)) | journal=Sarcoma | title=Long-Term Follow-up of a Randomized Study of Oral Etoposide versus Viscum album Fermentatum Pini as Maintenance Therapy in Osteosarcoma Patients in Complete Surgical Remission after Second Relapse | volume=2020 | pages=e8260730 | date=27 April 2020 | url=https://www.hindawi.com/journals/sarcoma/2020/8260730/ | doi=10.1155/2020/8260730 | access-date=15 March 2023}}</ref>

A Phase 1, dose finding trial is being conducted on Iscador Pini in Israel. <ref>https://beta.clinicaltrials.gov/study/NCT04376931</ref><br />

A Phase 1, dose finding trial is being conducted on Iscador Pini in Israel. <ref>https://beta.clinicaltrials.gov/study/NCT04376931</ref>

 

==Pharmacologic Extraction==

==Pharmacologic Extraction==

*{{Cite book| publisher = SteinerBooks, Incorporated| isbn = 978-1-938685-33-0| last1 = Johnson| first1 = Steven| last2 = Winters| first2 = Nasha| last3 = Blanning| first3 = Adam| last4 = Debus| first4 = Marion| last5 = Faust| first5 = Paul| last6 = Hancock| first6 = Mark| last7 = Hinderberger| first7 = Peter| title = Mistletoe and the Emerging Future of Integrative Oncology| date = 2022-02-25}}

*{{Cite book| publisher = SteinerBooks, Incorporated| isbn = 978-1-938685-33-0| last1 = Johnson| first1 = Steven| last2 = Winters| first2 = Nasha| last3 = Blanning| first3 = Adam| last4 = Debus| first4 = Marion| last5 = Faust| first5 = Paul| last6 = Hancock| first6 = Mark| last7 = Hinderberger| first7 = Peter| title = Mistletoe and the Emerging Future of Integrative Oncology| date = 2022-02-25}}

*{{cite book | date= 2019 | title=Vademecum of Anthroposophic Medicines. Best Practices for Mistletoe Use in Cancer Care | publisher=Society of Anthroposophic Doctors in Germany | edition=4th | isbn=978-3-946951-06-3}}  

*{{cite book | date= 2019 | title=Vademecum of Anthroposophic Medicines. Best Practices for Mistletoe Use in Cancer Care | publisher=Society of Anthroposophic Doctors in Germany | edition=4th | isbn=978-3-946951-06-3}}

==Weblinks==

==Weblinks==